Navigation Links
Labopharm to host conference call to discuss FDA approval of once-daily RYZOLT(TM) on Tuesday, January 6, 2009 at 8:30 a.m. (ET)
Date:1/5/2009

LAVAL, QC, Jan. 5 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced that it will host a conference call on Tuesday, January 6, 2009 at 8:30 a.m. (ET) to discuss the U.S. Food and Drug Administration's (FDA) approval of its once-daily formulation of tramadol, RYZOLT(TM). Joining Mr. James R. Howard-Tripp, President and Chief Executive Officer of Labopharm Inc., will be John H. Stewart, President and Chief Executive Officer of Purdue Pharma L.P., Labopharm's marketing partner for RYZOLT in the United States.

To access the conference call by telephone, dial 416-644-3414 or 1-800-733-7560. Please connect approximately 15 minutes prior to the beginning of the call to ensure participation. The conference call will be archived for replay until Tuesday, January 13, 2009 at midnight. To access the archived conference call, dial 416-640-1917 or 1-877-289-8525 and enter the reservation number 21293677 followed by the number sign.

A live audio webcast of the conference call will be available at www.labopharm.com. Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to join the webcast. The webcast will be archived at the above web site for 30 days.

About Labopharm Inc.

Labopharm is an emerging leader in optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies. The Company's lead product, a unique once-daily formulation of tramadol, is being commercially launched in key markets globally and its second product, a novel formulation of trazodone for the treatment of major depressive disorder, is under regulatory review by the FDA. The Company also has a robust pipeline of follow-on products in both pre-clinical and clinical development. Labopharm's vision is to become an integrated, international, specialty pharmaceutical company with the capability to internally develop and commercialize its own products. For more information, please visit www.labopharm.com.


'/>"/>
SOURCE Labopharm Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Labopharm To Present Poster On Onset Of Analgesic Effect Of Once-Daily Tramadol At Congress Of The European Society Of Regional Anaesthesia And Pain Therapy
2. Labopharm provides update on U.S. regulatory process for once-daily Tramadol
3. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
4. Labopharm appeals FDAs decision on once-daily tramadol
5. Labopharm to host conference call Friday, November 9, 2007 at 8:30 a.m. (ET)
6. Labopharm to present at CIBC World Markets 18th Annual Healthcare Conference
7. Labopharm Reports Results for Third Quarter Fiscal 2007
8. Labopharm receives FDA response to appeal of Approvable Letter for once-daily tramadol
9. Labopharm enters into licensing and distribution agreement for once-daily tramadol in Australia with iNova
10. Canadian Marketing and Sales Effort for Labopharms Once-Daily Tramadol Product to Expand Significantly
11. Labopharm Reports Positive Results for Phase III Study on Once-daily Trazodone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... ... ... of a visit to San Francisco , fall is a great time to visit. ... Business Architecture Associates is pleased to offer 5 days of training courses, available to the ... individuals, and as 4-½ day corporate package for up to 3 employees with the option ...
(Date:5/24/2017)... ... 2017 , ... Technique, technique, technique – with a dash of common sense. ... training and exercise or simply lifting heavy objects, advises Dr. Kaliq Chang, interventional pain ... Chang says. “Improper technique in lifting anything heavy or an attempt to lift too ...
(Date:5/23/2017)... (PRWEB) , ... May 23, 2017 , ... ... the pharmaceutical and medical device sectors, today announced the winners of its 3rd ... Entrepreneurs) represent the most influential people in the healthcare industry today. , Out ...
(Date:5/23/2017)... ... 2017 , ... London, May 23, 2017: Walter Schindler, the Founder and Managing ... Guest Speaker and Contributor to a weeklong series of classes, meetings, field trips and ... , Walter Schindler and SAIL Capital have received an increasing number ...
(Date:5/23/2017)... ... 2017 , ... Diagnotes, an Indianapolis-based digital healthcare communication company, ... secure clinical communication platform. The platform allows clinicians to easily escalate their preferred ... urgency of a situation. , “We know from our daily lives that ...
Breaking Medicine News(10 mins):
(Date:5/23/2017)... May 23, 2017  Leaf Healthcare, recognized for ... devices for pressure ulcer prevention, will unveil its ... of Critical Care Nurses, National Teaching Institute and ... The Leaf Patient Monitoring System is the ... hospital environment.  The system seamlessly tracks patient movement ...
(Date:5/18/2017)... -- Two Bayer U.S. Pharmaceutical leaders received top awards from ... th Woman of the Year event ... mission of furthering the advancement and impact of women ... Powell-Steffen , senior director of brand activation and inside ... Howe , a regional business manager for New England ...
(Date:5/15/2017)... , May 15, 2017 Enterin Inc., a privately-held ... and developing novel compounds to treat Parkinson,s disease (PD), has ... is a Phase 1/2a randomized, controlled, multicenter study involving patients ... will enroll 50 patients over a 9-to-12-month period. The first ... 10 patients with PD. Participating sites include Denver ...
Breaking Medicine Technology: